WO2002060449A3 - Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate - Google Patents

Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate Download PDF

Info

Publication number
WO2002060449A3
WO2002060449A3 PCT/EP2001/015324 EP0115324W WO02060449A3 WO 2002060449 A3 WO2002060449 A3 WO 2002060449A3 EP 0115324 W EP0115324 W EP 0115324W WO 02060449 A3 WO02060449 A3 WO 02060449A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitrates
pyrimidine
failure
thienopyrimidines
pharmaceutical formulation
Prior art date
Application number
PCT/EP2001/015324
Other languages
English (en)
French (fr)
Other versions
WO2002060449A2 (de
Inventor
Hans-Michael Eggenweiler
Volker Eiermann
Pierre Schelling
Original Assignee
Merck Patent Gmbh
Hans-Michael Eggenweiler
Volker Eiermann
Pierre Schelling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001104095 external-priority patent/DE10104095A1/de
Priority claimed from DE2001104096 external-priority patent/DE10104096A1/de
Priority claimed from DE2001104097 external-priority patent/DE10104097A1/de
Priority to US10/470,485 priority Critical patent/US20040077664A1/en
Priority to CA002436209A priority patent/CA2436209A1/en
Priority to MXPA03006717A priority patent/MXPA03006717A/es
Priority to PL01362408A priority patent/PL362408A1/xx
Priority to SK1076-2003A priority patent/SK10762003A3/sk
Application filed by Merck Patent Gmbh, Hans-Michael Eggenweiler, Volker Eiermann, Pierre Schelling filed Critical Merck Patent Gmbh
Priority to EP01988079A priority patent/EP1355649A2/de
Priority to BR0116849-5A priority patent/BR0116849A/pt
Priority to KR10-2003-7010043A priority patent/KR20030070149A/ko
Priority to HU0302987A priority patent/HUP0302987A2/hu
Priority to JP2002560641A priority patent/JP2004517940A/ja
Publication of WO2002060449A2 publication Critical patent/WO2002060449A2/de
Publication of WO2002060449A3 publication Critical patent/WO2002060449A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmazeutische Zubereitung enthaltend mindestens ein Pyrazolo (4, 3-d)pyrimidin oder Thienopyrimidin Phosphodiesterase V -Hemmer und mindestens ein Nitrat zur Herstellung eines Arzneimittels zur Behandlung von Angina, Bluthochdruck, pulmonalem Hochdruck, congestivem Herzversagen (CHF), chronischer obstruktiver pulmonaler Krankheit (COPD), Cor pulmonale, Rechtsherzinsuffizienz, Atherosklerose, Bedingungen verminderter Durchgängigkeit der Herzgefäße, peripheren vaskulären Krankheiten, Schlaganfall, Bronchitis, allergischem Asthma, chronischem Asthma, allergischer Rhinitis, Glaucom, Irritable Bowel Syndrome, Tumoren, Niereninsuffizienz und Leberzirrhose.
PCT/EP2001/015324 2001-01-31 2001-12-27 Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate WO2002060449A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2002560641A JP2004517940A (ja) 2001-01-31 2001-12-27 ピラゾロ［４，３−ｄ］ピリミジンおよびニトレートまたはチエノピリミジンおよびニトレートを含む医薬製剤
HU0302987A HUP0302987A2 (hu) 2001-01-31 2001-12-27 Pirazolo [4,3-d] pirimidinszármazékokat vagy tienopirimidinszármazékokat és nitrátvegyületeket tartalmazó gyógyászati készítmények
KR10-2003-7010043A KR20030070149A (ko) 2001-01-31 2001-12-27 피라졸로[４,３-ｄ]피리미딘 및 나이트레이트 또는티에노피리미딘 및 나이트레이트를 포함하여 이루어지는약제학적 조성물
CA002436209A CA2436209A1 (en) 2001-01-31 2001-12-27 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
MXPA03006717A MXPA03006717A (es) 2001-01-31 2001-12-27 Formulacion farmaceutica que comprende pirazolo (4,3-d) pirimidinas y nitratos o tienopirimidinas y nitratos.
PL01362408A PL362408A1 (en) 2001-01-31 2001-12-27 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
SK1076-2003A SK10762003A3 (sk) 2001-01-31 2001-12-27 Farmaceutický prostriedok obsahujúci parazolo-[4,3-d]pyrimidíny a nitráty alebo tienopyrimidíny a nitráty
US10/470,485 US20040077664A1 (en) 2001-01-31 2001-12-27 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
EP01988079A EP1355649A2 (de) 2001-01-31 2001-12-27 Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate
BR0116849-5A BR0116849A (pt) 2001-01-31 2001-12-27 Formulações farmacêuticas compreendendo pirazolo[4,3-d]pirimidinas e nitratos ou tienopirimidinas e nitratos

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10104096.2 2001-01-31
DE2001104095 DE10104095A1 (de) 2001-01-31 2001-01-31 Pharmazeutische Formulierung enthaltend Pyrazolo [4,3-d]pyrimidine und Nitrate
DE2001104097 DE10104097A1 (de) 2001-01-31 2001-01-31 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate
DE10104097.0 2001-01-31
DE2001104096 DE10104096A1 (de) 2001-01-31 2001-01-31 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate
DE10104095.4 2001-01-31

Publications (2)

Publication Number Publication Date
WO2002060449A2 WO2002060449A2 (de) 2002-08-08
WO2002060449A3 true WO2002060449A3 (de) 2003-01-30

Family

ID=27214255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/015324 WO2002060449A2 (de) 2001-01-31 2001-12-27 Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate

Country Status (14)

Country Link
US (1) US20040077664A1 (de)
EP (1) EP1355649A2 (de)
JP (1) JP2004517940A (de)
KR (1) KR20030070149A (de)
CN (1) CN1499969A (de)
AR (1) AR035741A1 (de)
BR (1) BR0116849A (de)
CA (1) CA2436209A1 (de)
CZ (1) CZ20032339A3 (de)
HU (1) HUP0302987A2 (de)
MX (1) MXPA03006717A (de)
PL (1) PL362408A1 (de)
SK (1) SK10762003A3 (de)
WO (1) WO2002060449A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005011784D1 (de) * 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
WO2006126718A1 (ja) * 2005-05-27 2006-11-30 Tanabe Seiyaku Co., Ltd. ピラゾロピリミジン誘導体
EP1941876A1 (de) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbidmononitrit Derivate zur Behandlung von der Inflammation und okularen Hypertension
JP6042331B2 (ja) 2010-07-23 2016-12-14 プレジデント アンド フェローズ オブ ハーバード カレッジ プロテアソーム活性を向上させる三環系化合物
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
EP2806875B1 (de) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Verbindungen zur modulierung einer proteasomaktivität
SE542968C2 (en) 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof

Also Published As

Publication number Publication date
EP1355649A2 (de) 2003-10-29
CA2436209A1 (en) 2002-08-08
US20040077664A1 (en) 2004-04-22
CN1499969A (zh) 2004-05-26
JP2004517940A (ja) 2004-06-17
HUP0302987A2 (hu) 2003-12-29
BR0116849A (pt) 2004-02-25
WO2002060449A2 (de) 2002-08-08
KR20030070149A (ko) 2003-08-27
PL362408A1 (en) 2004-11-02
CZ20032339A3 (cs) 2004-09-15
SK10762003A3 (sk) 2004-01-08
AR035741A1 (es) 2004-07-07
MXPA03006717A (es) 2003-10-24

Similar Documents

Publication Publication Date Title
WO2002041896A3 (de) Verwendung von thienopyrimidinen
WO2004024728A3 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
WO2003066060A3 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
WO2002060449A3 (de) Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate
WO2005003101A3 (en) Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2002096905A8 (en) Thiazole compounds useful as inhibitors of protein kinases
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
CA2487365A1 (en) Piperidine derivatives as potassium channel blockers
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
WO2005113534A3 (en) Cxcr1 and cxcr2 chemokine antagonists
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
BR0115995A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
CA2252982A1 (en) Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
CA2195677A1 (en) Endothelin antagonists
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
CA2460865A1 (en) Quinoline derivatives as neuropeptide y antagonists
WO2002100858A3 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
WO2006011024A3 (en) New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
BR0206853A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
SK1452000A3 (en) Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
WO2002041880A3 (de) Verwendung von pyrazolo[4,3-d]pyrimidinen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001988079

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500620

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006717

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2436209

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037010043

Country of ref document: KR

Ref document number: 10470485

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002240879

Country of ref document: AU

Ref document number: 2002560641

Country of ref document: JP

Ref document number: 018224385

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1066/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 10762003

Country of ref document: SK

WWP Wipo information: published in national office

Ref document number: 1020037010043

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003/06730

Country of ref document: ZA

Ref document number: 200306730

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2003-2339

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001988079

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-2339

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001988079

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2003-2339

Country of ref document: CZ